Institute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, USA.
Institute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, USA; Department of Pathology and Cell Biology, Herbert Irvine Comprehensive Cancer Center, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, USA; Division of Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, USA; Department of Immunology and Microbiology, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032, USA.
DNA Repair (Amst). 2024 Aug;140:103690. doi: 10.1016/j.dnarep.2024.103690. Epub 2024 May 25.
DNA strand breaks activate Poly(ADP-ribose) polymerase (PARP) 1 and 2, which use NAD+ as the substrate to covalently conjugate ADP-ribose on themselves and other proteins (e.g., Histone) to promote chromatin relaxation and recruit additional DNA repair factors. Enzymatic inhibitors of PARP1 and PARP2 (PARPi) are promising cancer therapy agents that selectively target BRCA1- or BRCA2- deficient cancers. As immediate early responders to DNA strand breaks with robust activities, PARP1 and PARP2 normally form transient foci (<10 minutes) at the micro-irradiation-induced DNA lesions. In addition to enzymatic inhibition, PARPi also extend the presence of PARP1 and PARP2 at DNA lesions, including at replication forks, where they may post a physical block for subsequent repair and DNA replication. The dynamic nature of PARP1 and PARP2 foci made live cell imaging a unique platform to detect subtle changes and the functional interaction among PARP1, PARP2, and their regulators. Recent imaging studies have provided new understandings of the biological consequence of PARP inhibition and uncovered functional interactions between PARP1 and PARP2 and new regulators (e.g., histone poly(ADP-ribosylation) factor). Here, we review recent advances in dissecting the temporal and spatial Regulation of PARP1 and PARP2 at DNA lesions and discuss their physiological implications on both cancer and normal cells.
DNA 链断裂激活聚(ADP-核糖)聚合酶 1 和 2(PARP1 和 PARP2),它们利用 NAD+作为底物,将 ADP-核糖共价结合到自身和其他蛋白质(如组蛋白)上,以促进染色质松弛并募集其他 DNA 修复因子。PARP1 和 PARP2 的酶抑制剂(PARPi)是有前途的癌症治疗剂,它们选择性地针对 BRCA1 或 BRCA2 缺陷型癌症。作为 DNA 链断裂的即时早期反应者,PARP1 和 PARP2 通常在微照射诱导的 DNA 损伤处形成短暂焦点(<10 分钟)。除了酶抑制作用外,PARPi 还延长了 PARP1 和 PARP2 在 DNA 损伤处的存在,包括在复制叉处,它们可能在随后的修复和 DNA 复制中形成物理障碍。PARP1 和 PARP2 焦点的动态性质使活细胞成像成为一种独特的平台,可以检测细微变化以及 PARP1、PARP2 及其调节剂之间的功能相互作用。最近的成像研究提供了对 PARP 抑制的生物学后果的新认识,并揭示了 PARP1 和 PARP2 之间以及新调节剂(如组蛋白多聚(ADP-核糖)化因子)之间的功能相互作用。在这里,我们回顾了在 DNA 损伤处解析 PARP1 和 PARP2 的时空调控的最新进展,并讨论了它们对正常细胞和癌细胞的生理意义。